Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

816
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
816
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data - a database study in the British population.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2025
Same author

Antidepressant drug switching in the Swiss population with a focus on Escitalopram and drugs with pharmacogenetic dosing guidelines: a drug utilization study using claims data.

The pharmacogenomics journal·2025
Same author

The risk of acute infections in new users of antidepressants: An observational cohort study.

Journal of affective disorders·2024
Same author

Determining the neurocognitive profile of children with tuberous sclerosis complex within the Western Cape region of South Africa.

Journal of intellectual disability research : JIDR·2023
Same author

Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group.

The British journal of dermatology·2021
Same author

Tuberous sclerosis complex in the Western Cape, South Africa: The clinical presentation features.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2017

相关实验视频

Updated: May 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

HMG-CoA减小酶抑制剂和骨折的风险

C R Meier1, R G Schlienger, M E Kraenzlin

  • 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. Christoph.Meier@unibas.ch

JAMA
|June 24, 2000
PubMed
概括

降胆固醇药的一种类型的他类药物,在50岁以上的人群中显著降低骨折风险. 这与纤维酸和其他降脂药物形成鲜明对比,这些药物对骨折预防没有显著影响.

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 骨的新陈代谢 骨的新陈代谢
  • 流行病学 流行病学

背景情况:

  • 动物研究表明,HMG-CoA减少酶抑制剂 (他类药物) 增强骨形成,体积和密度.
  • 关于他类药物使用与骨折风险之间的联系的人类数据有限.

研究的目的:

  • 调查他类药物,纤维酸盐或其他降脂药物是否与骨折风险降低有关.
  • 评估降脂药物对骨健康结果的影响.

主要方法:

  • 基于人口的,嵌套的病例对照研究,使用英国通用实践研究数据库 (GPRD).
  • 分析包括超过91,000名50岁以上的个人,将骨折病例 (n=3940) 与对照病例 (n=23,379) 进行比较.
  • 根据BMI,吸烟,医生访问,皮质类固醇和雌激素使用情况进行调整.

主要成果:

  • 当前使用他类药物显著与骨折风险降低有关 (调整后OR,0.55;95%CI,0.44-0.69).
  • 纤维酸和其他降脂药物与骨折风险降低没有显著关联.
  • 纤维化物和其他降脂药物的调整后几率比分分别为0.87 (95% CI,0.70-1.08) 和0.76 (95% CI,0.41-1.39).

更多相关视频

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

9.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

相关实验视频

Last Updated: May 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

9.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

结论:

  • 目前的他类药物暴露似乎与50岁及以上的个体骨折风险较低有关.
  • 这些发现表明,他类药物对骨健康有潜在的公共卫生益处.
  • 建议通过前性试验进一步确认.